International Diabetes Federation Meeting, 1997: Nephropathy, retinopathy, and glycation

Diabetes Care

Volumn 21, Issue 9, 1998, Pages 1560-1566

  Bloomgarden, Zachary T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FISH OIL; INSULIN; LISINOPRIL; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; PERINDOPRIL; PICOTAMIDE; PROTEIN DERIVATIVE; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SULFONYLUREA; SULODEXIDE; TENILSETAM; UNCLASSIFIED DRUG;

BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; GLYCATION; HUMAN; KIDNEY FAILURE; METABOLIC REGULATION; PROGNOSIS; PROTEINURIA; RECEPTOR BINDING; REVIEW;

EID: 0031780450     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.9.1560     Document Type: Review

References (14)

1. Poulsen PL, Hansen KW, Mogensen CE: Ambulatory blood pressure in the transition from normoto microalbuminuria: a longitudinal study in IDDM patients. Diabetes 43:1248-1253, 1994
2. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787-1792, 1997
3. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341:1306-1309, 1993
4. The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276:1409-1415, 1996
5. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, Gries FA, Keen H: Protein intake and urinary albumin excretion rates in the EURODIAB Type 1 Diabetes Complications Study. Diabetologia 40:1219-1226, 1997
6. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a metaanalysis. Ann Intern Med 124:627-632, 1996
7. Rodby RA, Firth LM, Lewis EJ: An economic analysis of captopril in the treatment of diabetic nephropathy: the Collaborative Study Group. Diabetes Care 19:1051-1061, 1996
8. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39:587-593, 1996
9. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive type 2 diabetes patients. Diabetes 45:216-222, 1996
10. Purkerson ML, Tollefsen DM, Klahr S: N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 81:69-74, 1988
11. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42:285-291, 1992
12. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J, Kluft C, Jespersen J, Deckert T: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345:421-422, 1995
13. Tamsma JT, van der Woude FJ, Lemkes HH: Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant 11:182-185, 1996
14. Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller J: Retinopathy and vision loss in insulin-dependent diabetes in Europe: the EURO-DIAB IDDM Complications Study. Ophthalmology 104:252-260, 1997